Enjoy complimentary customisation on priority with our Enterprise License!
Technavio’s market research report has identified the advent of new innovative combination drugs to be one of the primary factors driving the growth of the glaucoma therapeutics market till 2021. To control the elevated intraocular pressure (IOP), healthcare physicians recommend a combination of two or more drugs for about 40%-45% of the glaucoma patients. According to clinical studies , the prescription of fixed combination therapies for glaucoma is more effective in lowering IOP than individual therapeutic agents. Moreover, the prescription of fixed combination also simplifies the medical regimen. Cosopt (timolol/dorzolamide), combigan (timolol/brimonidine), xalacom (timolol/latanoprost), ganfort (timolol/bimatoprost), and duotrav (timolol/travoprost) are the common combination drugs used for glaucoma. Technavio’s market research analysts estimate that this market will register a revenue of more than USD 8 billion by 2021.
The emergence of new drug delivery techniques such as the adoption of various strategies to provide the drug with a carrier to hold the drug on the surface of the cornea for a longer duration benefits patients by reducing the frequency of doses. This will in turn, improve the patients’ adherence and compliance to the medication. According to our market research analysts, the emergence of new drug delivery methods will be one of the key trends that will gain traction in the glaucoma therapeutics market during the next few years.
The glaucoma therapeutics market is characterized by the presence of key companies and the vendors compete against each other mainly based on factors such as product efficacy, prolonged action, limited side effects, rich pipeline, and operational base. The players in this marketspace are increasingly focusing on launching novel therapies and are investing heavily in R&D activities to improve their market positions.
Key vendors in this market are -
Other prominent vendors in the market include Bayer HealthCare, Akorn, Bausch & Lomb, Santen Pharmaceutical, Teva Pharmaceutical, and VISTAKON.
The prostaglandin analogs segment accounted for the majr shares of the glaucoma therapeutics market during 2016. Prostaglandin analogs are extensively adopted for the treatment of open-angle glaucoma since they are more effective than the other drugs. Latanoprost, bimatoprost, travoprost, and tafluprost are the four prostaglandin analogs that are available in the market for the treatment of glaucoma. It has been observed that the administration of tafluprost, travoprost, and latanoprost has shown an IOP-lowering ability of 25%-32% during clinical trials. Similarly, bimatoprost showed IOP-lowering ability of 27%-32%.
The consumption of glaucoma drugs in the Americas is increasing due to the rising incidence of glaucoma in countries such as the US. Owing to its heavy investments in the healthcare sector, the US the major revenue contributor to the glaucoma therapeutics market in this region. With the presence of pharmaceutical giants and huge investments in the pharmaceutical industry, the need for glaucoma therapeutics will increase in the region during the predicted period.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: RESEARCH METHODOLOGY
PART 03: INTRODUCTION
PART 04: MARKET LANDSCAPE
PART 05: PIPELINE LANDSCAPE
PART 06: MARKET SEGMENTATION BY DRUG CLASS
PART 07: REGIONAL LANDSCAPE
PART 08: DECISION FRAMEWORK
PART 09: DRIVERS AND CHALLENGES
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
PART 12: KEY VENDOR ANALYSIS
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.